Antivirally active ribavirin analogues - 4,5-disubstituted 1,2,3-triazole nucleosides: Biological evaluation against certain respiratory viruses and computational modelling

Antiviral Chemistry and Chemotherapy

Volumn 23, Issue 4, 2014, Pages 161-171

  Krajczyk, Anna ^a   Kulinska, Katarzyna ^a   Kulinski, Tadeusz ^a   Hurst, Brett L ^b   Day, Craig W ^b   Smee, Donald F ^b   Ostrowski, Tomasz ^a   Januszczyk, Piotr ^a   Zeidler, Joanna ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^b UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; 5 BROMO 1 (BETA D RIBOFURANOSYL) 1H[1,2,3]TRIZOLE 4 CARBOXAMIDE; ADENOSINE TRIPHOSPHATE; ALKYNYL 1,2,3 TRIAZOLE; GUANOSINE TRIPHOSPHATE; RIBAVIRIN DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DRUG BINDING; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; MEASLES VIRUS; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MEASLES; MEASLES VIRUS; MODELS, MOLECULAR; NUCLEOSIDES; ORTHOMYXOVIRIDAE INFECTIONS; PARAINFLUENZA VIRUS 3, HUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIROVIRUS INFECTIONS; RIBAVIRIN; TRIAZOLES;

EID: 84893173479     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2564     Document Type: Article

References (52)

1. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of virazole: 1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177:705-706.
2. Witkowski JT, Robins RK, Sidwell RW, Simon LN. Design, synthesis, and broad spectrum antiviral activity of 1-b-Dribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 1972; 15:1150-1154.
3. Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther 2011; 9:27-32.
4. Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep 2013; 15:305.
5. Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res 2005; 107:165-171.
6. Leyssen P, De Clercq E, Neyts J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 2008; 78:9-25.
7. Streeter DG, Witkowski JT, Khare GP, et al. Mechanism of action of 1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A 1973; 70:1174-1178.
8. Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005; 79:1943-1947.
9. Smee DF, Bray M, Huggins JW. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir Chem Chemother 2001; 12:327-335.
10. Bougie I, Bisaillon M. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 2004; 279:22124-22130.
11. Eriksson B, Helgstrand E, Johansson NG, et al. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977; 11:946-951.
12. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001; 98:6895-6900.
13. Lanford RE, Chavez D, Guerra B, et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 2001; 75:8074-8081.
14. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76:8505-8517.
15. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 2003; 77:481-488.
16. Day CW, Smee DF, Julander JG, Yamshchikov VF, Sidwell RW, Morrey JD. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res 2005; 67:38-45.
17. Shah NR, Sunderland A, Grdzelishvili VZ. Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS ONE 2010; 5:e11265.
18. De Clercq E, Cools M, Balzarini J, et al. Antiviral activities of 5-ethynyl-1-b-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob Agents Chemother 1991; 35:679-684.
19. Balzarini J, Karlsson A, Wang L, et al. Eicar (5-ethynyl-1-b-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J Biol Chem 1993; 268:24591-24598.
20. Wang W, Papov VV, Minakawa N, Matsuda A, Biemann K, Hedstrom L. Inactivation of inosine 5′-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-b-Dribofuranosylimidazole-4-carboxamide 5′-monophosphate. Biochemistry 1996; 35:95-101.
21. Moya J, Pizarro H, Jashes M, De Clercq E, Sandino AM. In vivo effect of EICAR (5-ethynyl-1-b-Dribofuranosylimidazole-carboxamide) on experimental infected rainbow trout (Oncorhynchus mykiss) and coho salmon (Oncorhynchus kisutch) fry with infectious pancreatic necrosis virus. Antiviral Res 2000; 48:125-130.
22. Dal Pozzo F, Galligioni V, Vaccari F, Gallina L, Battilani M, Scagliarini A. Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro. Res Vet Sci 2010; 88:339-344.
23. Chung DH, Kumarapperuma SC, Sun Y, et al. Synthesis of 1-b-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. Antiviral Res 2008; 79:19-27.
24. McDowell M, Gonzales SR, Kumarapperuma SC, Jeselnik M, Arterburn JB, Hanley KA. A novel nucleoside analog, 1-b-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro. Antiviral Res 2010; 87:78-80.
25. Wan J, Xia Y, Liu Y, et al. Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity. J Med Chem 2009; 52:1144-1155.
26. Moriyama K, Suzuki T, Negishi K, et al. Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity. J Med Chem 2008; 51:159-166.
27. Ostrowski T, Zeidler J. Synthesis of 5-ethynyl-1-b-Dribofuranosyl-1H-[1-3]triazole-4-carboxylic acid amide (isosteric to EICAR) and its derivatives. Nucleic Acids Symp Ser 2008; 52:585-586.
28. Ostrowski T, Januszczyk P, Cieslak M, et al. 5-Ethynyl-1-b-D-ribofuranosyl-1H-[1-3]triazole-4-carboxylic acid amide (ETCAR) and its analogues: synthesis and cytotoxic properties. Bioorg Med Chem 2011; 19:4386-4398.
29. Biagi G, Giorgi I, Livi O, Scartoni V. Synthesis of new 2-substituted 9-b-D-ribofuranosyl-8-azahypoxanthines. Farmaco 1992; 47:525-536.
30. Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 2001; 45:743-748.
31. Smee DF, Morrison AC, Barnard DL, Sidwell RW. Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J Virol Methods 2002; 106:71-79.
32. Risel D, Strickler MD, Goldstein BM. Crystal structure of human inosine monophosphate dehydrogenase type II complexed with the MPA/NAD analog C2-MAD. RCSB Protein Data Bank 2004; doi: 10.2210/pdb1nf7/pdb.
33. Wu G, Robertson DH, Brooks CL, III, Vieth M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 2003; 24:1549-1562.
34. Smee DF, Hurst BL, Day CW. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 2012; 22:263-272.
35. Ostrowski T, Januszczyk P, Cieslak M, et al. 5-Ethynyl-1-b-D-ribofuranosyl-1H-[1-3]triazole-4-carboxylic acid amide (ETCAR) and its analogues: synthesis and cytotoxic properties. Bioorg Med Chem 2011; 19:4386-4398.
36. Malnuit V, Duca M, Mantuo A, Bougrin K, Benhida R. Tandem azide-alkyne 1,3-dipolar cycloaddition/ electrophilic addition: a concise three-component route to 4,5-disubstituted triazolyl-nucleosides. Synlett 2009; 2009:2123-2126.
37. Li L, Li Y, Li R, Zhu A, Zhang G. A new synthetic protocol for one-pot preparations of 5-halo-1,4-disubstituted-1,2,3-triazoles. Aust J Chem 2011; 64:1383-1389.
38. Li L, Li R, Zhu A, Zhang G, Zhang L. CuBr-NCS-mediated multicomponent azide-alkyne cycloaddition: mild and efficient synthesis of 5-bromo-1,4-disubstituted-1,2,3-triazoles. Synlett 2011; 2011:874-878.
39. Ackermann L, Potukuchi HK. Regioselective syntheses of fully-substituted 1,2,3-triazoles: the CuAAC/C-H bond functionalization nexus. Org Biomol Chem 2010; 8:4503-4513.
40. Li L, Zhang G, Zhu A, Zhang L. A convenient preparation of 5-iodo-1,4-disubstituted-1,2,3-triazole: multicomponent one-pot reaction of azide and alkyne mediated by CuI-NBS. J Org Chem 2008; 73:3630-3633.
41. Oziminski WP, Dobrowolski JC, Mazurek AP. DFT studies on tautomerism of C5-substituted 1,2,4-triazoles. J Mol Struct THEOCHEM 2004; 680:107-115.
42. Prosise GL, Wu JZ, Luecke H. Crystal structure of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with the inhibitor ribavirin monophosphate reveals a catalysis-dependent ion-binding site. J Biol Chem 2002; 277:50654-50659.
43. Sintchak MD, Nimmesgern E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000; 47:163-184.
44. Prusiner P, Sundaralingam M. The crystal and molecular structures of two polymorphic crystalline forms of virazole (1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide). A new synthetic broad sprectrum antiviral agent. Acta Crystallogr 1976; B32:415-419.
45. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276:46094-46098.
46. Vo NV, Young KC, Lai MM. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 2003; 42:10462-10471.
47. Patton GC, Stenmark P, Gollapalli DR, et al. Cofactor mobility determines reaction outcome in the IMPDH and GMPR (b-a)8 barrel enzymes. Nat Chem Biol 2011; 7:950-958.
48. Guillén Schlippe YV, Hedstrom L. Is Arg418 the catalytic base required for the hydrolysis step of the IMP dehydrogenase reaction? Biochemistry 2005; 44:11700-11707.
49. Miles DL, Miles DW, Eyring H. A conformational basis for the antiviral inactivity of tetrazole ribonucleosides. Biochim Biophys Acta 1978; 518:17-30.
50. Naik SR, Witkowski JT, Robins RK. Synthesis of nucleosides of 5-substituted-1,2,4-triazole-3-carboxamides. J Heterocycl Chem 1974; 11:57-61.
51. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 2010; 5:e9332.
52. De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006; 5:1015-1025.